CataractCaff2NCT03534973
Prevention of UV- Induced Apoptosis by Caffeine
A study testing Caffeine intake and No caffeine intake in people with Cataract, run by Vienna Institute for Research in Ocular Surgery at 1 site in Austria.
Trial summary
Investigate if caffeine accumulation in human lens epithelial cells after oral caffeine intake is sufficient to prevent from experimental ultraviolet radiation induced apoptosis Read more about this study
- Who is it for?
- Ages 21 to 105 years
- Conditions the study is for
- Cataract
- What is being tested?
- Caffeine intake and No caffeine intake
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 1 siteAustria
- Study dates
- 17 Apr 2018to 1 Jan 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 105 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age > 21 years
- Cataract
- Patients who chose pseudoanalgesia technique for cataract surgery before recruitment process
- Written informed consent prior to surgery
Who cannot join
- Age < 21 years
- Beverages containing caffeine (such as Coffee, Coca Cola, energy drinks, black or green tea) and dark chocolate consumption 1 week before surgery
- Pseudoexfoliation syndrome of the lens
- Systolic hypertension of >160 at the day of surgery
- Pregnancy (pregnancy test will be taken in women of reproductive age)
Trial locations and contacts
1 site in 1 country.
Austria1 site, 1 recruiting
- Recruiting
Vienna Institute for Research in Ocular Surgery (VIROS)
Vienna, 1140
Martin Kronschlaeger, MD, 01 91021-57572, martin.kronschlaeger@gmx.at
Manuel Ruiß, Mac, 01 90121-57564, m.ruiss@viros.at
About this study
Official title: Prevention of Experimental Ultraviolet Induced Apoptosis in Explanted Human Lens Epithelial Cells Enriched With Caffeine: a Pilot Study
Investigate if caffeine accumulation in human lens epithelial cells after oral caffeine intake is sufficient to prevent from experimental ultraviolet radiation induced apoptosis
Read the detailed description
Caffeine is a worldwide consumed dietary constituent. It occurs in a variety of beverages such as coffee, tea, soft drinks and cocoa beverages, and in chocolate-based food products. In the United States there is a reported average intake of caffeine of 200 mg/d in 80 % of adults corresponding to the amount in two 5-ounce cups of coffee or four sodas. A new interest for caffeine in ophthalmology emerged with the observation that caffeine inhibits cataractogenesis.
Cataract is the leading cause of blindness worldwide and until now there is no approved drug to prevent cataract. UVR-B radiation has been identified as one of the major risk factors for age related cataract. In vitro, Varma showed that caffeine preserves ATP levels and GSH levels in the lens when exposed to UVR-B and further maintains the state of transparency in the lens. Varma moreover hypothesized that its protective effect in the lens is due to its ability to scavenge reactive oxygen species (ROS) and to suppress elevation of toxic microRNAs and consequent gene silencing. In the galactosemic rat model, Varma demonstrated that topical caffeine in vivo inhibited the formation of galactose cataract and prevented apoptosis of lens epithelial cells.
A further study presented evidence that topical caffeine also prevents in vivo UVR-B induced cataract and inhibits apoptosis of lens epithelial cells. The investigators estimated the protection factor (PF) of caffeine to 1.23. The PF is identical to PF for sunscreens; the ratio between the threshold dose of the toxic agent and the threshold dose without the toxic agent. The PF observed for topically applied caffeine was higher than the PF observed for perorally administered vitamin E (PF: 1.14) and vitamin C (PF: 1) , respectively. Only the Grx gene provides a higher PF (PF 1.3). This strongly supports that caffeine has an important antioxidant capacity in vivo.
Up to 99 % of caffeine is gastrointestinally absorbed and pharmacokinetics are comparable after oral and i.v. administration. In the liver, caffeine is metabolized by hepatic enzymes belonging to the cytochrome P-450 family, mainly CYP1A2. Major metabolites like 1-methylxanthine and 1-methyl uric acid were reported to still have significant antioxidant activity. Recently, a study confirmed the protective effect of coffee combined with additional antioxidant dietary against age-related cataract. Its hydrophobic properties allow caffeine passage over all biological membranes. A further study found that caffeine after oral intake accumulates in the lens epithelium.
The lens epithelium plays a major role in balancing water, ions and the metabolic homeostasis. Additionally, the germinative cells in the lens epithelium generate a reservoir for lens fiber cell generation. UVR-B radiation is absorbed by proteins and DNA in the lens epithelium and underlying lens fibres, causing damage to the cells. When epithelial cells are damaged, lens growth and transparency is disturbed. Michael et al. demonstrated the appearance of apoptotic lens cells after in vivo exposure to UVR-B with transmission electron microscopy. No necrotic cells were found at threshold dose. We found a peak of Apoptosis hours after UVR-B exposure.
The present study aims to investigate if caffeine accumulation in human lens epithelial cells after oral caffeine intake is sufficient to prevent from experimental ultraviolet radiation induced apoptosis.
- Conditions
- Cataract
- Being tested
- Caffeine intake, No caffeine intake
- Keywords
- Cataract, Caffeine
- Medical subject headings
- Cataract
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Caffeine intakeOther
Cataract surgery in eyes with prior caffeine intake
No caffeine intakeOther
Cataract surgery in eyes without prior caffeine intake
| Study group | Role | What they receive |
|---|---|---|
| Caffeine intake | Active comparator | Caffeine is given orally prior to cataract surgery Receives: Other: Caffeine intake |
| No caffeine intake | Sham comparator | Caffeine is not given orally prior to cataract surgery Receives: Other: No caffeine intake |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of apoptotic and viable lens epithelial cells from eyes with and without oral caffeine intake
Using a cell apoptosis and viability assay the number of apoptotic and viable lens epithelial cells is counted under a fluorescence microscope
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 May 2018
- Study start17 Apr 2018
- Primary completion1 Dec 2019 (estimated)
- Study completion1 Jan 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CataractStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Vienna Institute for Research in Ocular Surgery
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Prim. Prof. Dr. Oliver Findl, MBA, Vienna Institute for Research in Ocular Surgery
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03534973
- Sponsor's protocol ID
- Caff2
- Acronym
- Caff2
- Status last verified
- Oct 2019
- First submitted
- 30 Apr 2018
- Last updated
- 2 Oct 2019
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevention of Experimental Ultraviolet Induced Apoptosis in Explanted Human Lens Epithelial Cells Enriched With Caffeine: a Pilot Study
- ClinicalTrials.gov ID
- NCT03534973
- Acronym / sponsor ID
- Caff2 / Caff2
- Conditions
- Cataract
- Keywords
- Cataract, Caffeine
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Vienna Institute for Research in Ocular SurgeryUniversity, hospital or other
- Study start
- 17 Apr 2018 (actual)
- Primary completion
- 1 Dec 2019 (estimated)
- Study completion
- 1 Jan 2020 (estimated)
- First posted
- 23 May 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Investigate if caffeine accumulation in human lens epithelial cells after oral caffeine intake is sufficient to prevent from experimental ultraviolet radiation induced apoptosis
Detailed description
Caffeine is a worldwide consumed dietary constituent. It occurs in a variety of beverages such as coffee, tea, soft drinks and cocoa beverages, and in chocolate-based food products. In the United States there is a reported average intake of caffeine of 200 mg/d in 80 % of adults corresponding to the amount in two 5-ounce cups of coffee or four sodas. A new interest for caffeine in ophthalmology emerged with the observation that caffeine inhibits cataractogenesis.
Cataract is the leading cause of blindness worldwide and until now there is no approved drug to prevent cataract. UVR-B radiation has been identified as one of the major risk factors for age related cataract. In vitro, Varma showed that caffeine preserves ATP levels and GSH levels in the lens when exposed to UVR-B and further maintains the state of transparency in the lens. Varma moreover hypothesized that its protective effect in the lens is due to its ability to scavenge reactive oxygen species (ROS) and to suppress elevation of toxic microRNAs and consequent gene silencing. In the galactosemic rat model, Varma demonstrated that topical caffeine in vivo inhibited the formation of galactose cataract and prevented apoptosis of lens epithelial cells.
A further study presented evidence that topical caffeine also prevents in vivo UVR-B induced cataract and inhibits apoptosis of lens epithelial cells. The investigators estimated the protection factor (PF) of caffeine to 1.23. The PF is identical to PF for sunscreens; the ratio between the threshold dose of the toxic agent and the threshold dose without the toxic agent. The PF observed for topically applied caffeine was higher than the PF observed for perorally administered vitamin E (PF: 1.14) and vitamin C (PF: 1) , respectively. Only the Grx gene provides a higher PF (PF 1.3). This strongly supports that caffeine has an important antioxidant capacity in vivo.
Up to 99 % of caffeine is gastrointestinally absorbed and pharmacokinetics are comparable after oral and i.v. administration. In the liver, caffeine is metabolized by hepatic enzymes belonging to the cytochrome P-450 family, mainly CYP1A2. Major metabolites like 1-methylxanthine and 1-methyl uric acid were reported to still have significant antioxidant activity. Recently, a study confirmed the protective effect of coffee combined with additional antioxidant dietary against age-related cataract. Its hydrophobic properties allow caffeine passage over all biological membranes. A further study found that caffeine after oral intake accumulates in the lens epithelium.
The lens epithelium plays a major role in balancing water, ions and the metabolic homeostasis. Additionally, the germinative cells in the lens epithelium generate a reservoir for lens fiber cell generation. UVR-B radiation is absorbed by proteins and DNA in the lens epithelium and underlying lens fibres, causing damage to the cells. When epithelial cells are damaged, lens growth and transparency is disturbed. Michael et al. demonstrated the appearance of apoptotic lens cells after in vivo exposure to UVR-B with transmission electron microscopy. No necrotic cells were found at threshold dose. We found a peak of Apoptosis hours after UVR-B exposure.
The present study aims to investigate if caffeine accumulation in human lens epithelial cells after oral caffeine intake is sufficient to prevent from experimental ultraviolet radiation induced apoptosis.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Caffeine intake | Active comparator | Other: Caffeine intakeCaffeine is given orally prior to cataract surgery |
| No caffeine intake | Sham comparator | Other: No caffeine intakeCaffeine is not given orally prior to cataract surgery |
Who may qualify
- Ages
- 21 to 105 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age > 21 years
- Cataract
- Patients who chose pseudoanalgesia technique for cataract surgery before recruitment process
- Written informed consent prior to surgery
Key exclusion criteria (5 listed)
- Age < 21 years
- Beverages containing caffeine (such as Coffee, Coca Cola, energy drinks, black or green tea) and dark chocolate consumption 1 week before surgery
- Pseudoexfoliation syndrome of the lens
- Systolic hypertension of >160 at the day of surgery
- Pregnancy (pregnancy test will be taken in women of reproductive age)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Caffeine intakeCataract surgery in eyes with prior caffeine intake | Other | Caffeine intake |
| No caffeine intakeCataract surgery in eyes without prior caffeine intake | Other | No caffeine intake |
Primary outcome
Number of apoptotic and viable lens epithelial cells from eyes with and without oral caffeine intake
Time frame: 12 months
Using a cell apoptosis and viability assay the number of apoptotic and viable lens epithelial cells is counted under a fluorescence microscope
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2019.
- Individual participant dataSharing planned: Undecided
Related trials for Cataract
Recruiting
Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
Glaucoma, Ocular Hypertension
Not yet recruiting
Trial to Investigate the Safety and Effectiveness of the KI-362-US1 (YP2.2VM) Intraocular Lens (IOL) in Adult Participants for Correction of Aphakia Following Cataract Extraction
Aphakia, Postcataract
Not yet recruiting
Effects of Oxygen Cage Support During Cataract Surgery
Cataract
Active, not recruitingObservational study
Age-Related Eye Disease Study (AREDS) Follow-Up
Age-Related Macular Degeneration, Cataract
RecruitingObservational study
Objective Depth-of-Focus Changes During Light Adjustable Lens UV Adjustments
Light Adjustable Lens, Objective Depth of Focus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Caffeine intake and No caffeine intake in people with Cataract, run by Vienna Institute for Research in Ocular Surgery at 1 site in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 2 Oct 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Martin Kronschlaeger, MD (01 91021-57572, martin.kronschlaeger@gmx.at), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of apoptotic and viable lens epithelial cells from eyes with and without oral caffeine intake (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2019.